Eric W. Lundstrom
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eric W. Lundstrom has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Gordon S. Smith
Department of Epidemiology and Biostatistics, School of Public Health, West Virginia University, Morgantown, US
3 shared publicationsBrian Hendricks
Department of Epidemiology and Biostatistics, School of Public Health, West Virginia University, Morgantown, US
2 shared publicationsCaroline P. Groth
Department of Epidemiology and Biostatistics, School of Public Health, West Virginia University, Morgantown, US
2 shared publicationsErin L. Winstanley
Department of Behavioral Medicine & Psychiatry, School of Medicine, West Virginia University, Morgantown, US
1 shared publicationJacob K. Pence
Eric W. Lundstrom and Gordon S. Smith are with the Department of Epidemiology and Biostatistics, West Virginia University, Morgantown. Jacob K. Pence is with the Transitional Year Residency Program, West Virginia University
1 shared publicationJames E. Harrison
College of Medicine and Public Health, Flinders University, Adelaide, South Australia
1 shared publication
Latest Publications
- Open Access
- 4 January 2024
- Published by Springer Nature in Substance Abuse Treatment, Prevention, and Policy
- Vol. 19 (1) , 1-13
Comparing the effects of decreasing prescription opioid shipments and the release of an abuse deterrent OxyContin formulation on opioid overdose fatalities in WV: an interrupted time series study
The 2010 release of an abuse deterrent formulation (ADF) of OxyContin, a brand name prescription opioid, has been cited as a major driver for the reduction in prescription drug misuse and the associated increasing illicit opioid use and overdose rates. However, studies of this topic often do not account for changes in supplies of other prescription opioids that were widely prescribed before and after the ADF OxyContin release, including generic oxycodone formulations and hydrocodone. We therefore sought to compare the impact of the ADF OxyContin release to that of decreasing prescription opioid supplies in West Virginia (WV). Opioid tablet shipment and overdose data were extracted from The Washington Post ARCOS (2006–2014) and the WV Forensic Drug Database (2005–2020), respectively. Locally estimated scatterplot smoothing (LOESS) was used to estimate the point when shipments of prescription opioids to WV began decreasing, measured via dosage units and morphine milligram equivalents (MMEs). Interrupted time series analysis (ITSA) was used to compare the impact LOESS-identified prescription supply changes and the ADF OxyContin release had on prescription (oxycodone and hydrocodone) and illicit (heroin, fentanyl, and fentanyl analogues) opioid overdose deaths in WV. Model fit was compared using Akaike Information Criteria (AIC). The majority of opioid tablets shipped to WV from 2006 to 2014 were generic oxycodone or hydrocodone, not OxyContin. After accounting for a 6-month lag from ITSA models using the LOESS-identified change in prescription opioid shipments measured via dosage units (2011 Q3) resulted in the lowest AIC for both prescription (AIC = -188.6) and illicit opioid-involved overdoses (AIC = -189.4), indicating this intervention start date resulted in the preferred model. The second lowest AIC was for models using the ADF OxyContin release as an intervention start date. We found that illicit opioid overdoses in WV began increasing closer to when prescription opioid shipments to the state began decreasing, not when the ADF OxyContin release occurred. Similarly, the majority of opioid tablets shipped to the state for 2006–2014 were generic oxycodone or hydrocodone. This may indicate that diminishing prescription supplies had a larger impact on opioid overdose patterns than the ADF OxyContin release in WV.
- 4 January 2024
- Published by Springer Nature in Substance Abuse Treatment, Prevention, and Policy
- Vol. 19 (1) , 1-13
Open AccessComparing the effects of decreasing prescription opioid shipments and the release of an abuse deterrent OxyContin formulation on opioid overdose fatalities in WV: an interrupted time series study
The 2010 release of an abuse deterrent formulation (ADF) of OxyContin, a brand name prescription opioid, has been cited as a major driver for the reduction in prescription drug misuse and the associated increasing illicit opioid use and overdose rates. However, studies of this topic often do not account for changes in supplies of other prescription opioids that were widely prescribed before and after the ADF OxyContin release, including generic oxycodone formulations and hydrocodone. We therefore sought to compare the impact of the ADF OxyContin release to that of decreasing prescription opioid supplies in West Virginia (WV). Opioid tablet shipment and overdose data were extracted from The Washington Post ARCOS (2006–2014) and the WV Forensic Drug Database (2005–2020), respectively. Locally estimated scatterplot smoothing (LOESS) was used to estimate the point when shipments of prescription opioids to WV began decreasing, measured via dosage units and morphine milligram equivalents (MMEs). Interrupted time series analysis (ITSA) was used to compare the impact LOESS-identified prescription supply changes and the ADF OxyContin release had on prescription (oxycodone and hydrocodone) and illicit (heroin, fentanyl, and fentanyl analogues) opioid overdose deaths in WV. Model fit was compared using Akaike Information Criteria (AIC). The majority of opioid tablets shipped to WV from 2006 to 2014 were generic oxycodone or hydrocodone, not OxyContin. After accounting for a 6-month lag from ITSA models using the LOESS-identified change in prescription opioid shipments measured via dosage units (2011 Q3) resulted in the lowest AIC for both prescription (AIC = -188.6) and illicit opioid-involved overdoses (AIC = -189.4), indicating this intervention start date resulted in the preferred model. The second lowest AIC was for models using the ADF OxyContin release as an intervention start date. We found that illicit opioid overdoses in WV began increasing closer to when prescription opioid shipments to the state began decreasing, not when the ADF OxyContin release occurred. Similarly, the majority of opioid tablets shipped to the state for 2006–2014 were generic oxycodone or hydrocodone. This may indicate that diminishing prescription supplies had a larger impact on opioid overdose patterns than the ADF OxyContin release in WV.
- 1 November 2023
- Published by American Public Health Association in American Journal of Public Health
- Vol. 113 (11) , 1163-1166
Impact of a Permitless Concealed Firearm Carry Law in West Virginia, 1999–2015 and 2016–2020
We used firearm mortality and sales data to assess the impact of HB 4145, a May 2016 law that legalized concealed firearm carry without a permit in West Virginia. Firearm mortality was significantly higher (29%) in the years after the enactment of the law; handgun mortality was also higher (45% increase), whereas long gun deaths and firearm sales were unaffected. This may suggest that HB 4145 increased rates of firearm-related mortality in West Virginia without affecting firearm sales in the state. (Am J Public Health. 2023;113(11):1163–1166. https://doi.org/10.2105/AJPH.2023.307382 )
- 1 November 2023
- Published by American Public Health Association in American Journal of Public Health
- Vol. 113 (11) , 1163-1166
Impact of a Permitless Concealed Firearm Carry Law in West Virginia, 1999–2015 and 2016–2020
We used firearm mortality and sales data to assess the impact of HB 4145, a May 2016 law that legalized concealed firearm carry without a permit in West Virginia. Firearm mortality was significantly higher (29%) in the years after the enactment of the law; handgun mortality was also higher (45% increase), whereas long gun deaths and firearm sales were unaffected. This may suggest that HB 4145 increased rates of firearm-related mortality in West Virginia without affecting firearm sales in the state. (Am J Public Health. 2023;113(11):1163–1166. https://doi.org/10.2105/AJPH.2023.307382 )
- Open Access
- 13 July 2023
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 6 (7) , e2323392
Excess US Firearm Mortality During the COVID-19 Pandemic Stratified by Intent and Urbanization
Published research1,2 suggests the COVID-19 pandemic exacerbated already increasing rates of overall US firearm mortality. Descriptive comparisons of 2019 to 2020 mortality data suggest this early trend was driven by homicides and urban firearm deaths.2 However, to our knowledge, no study has quantified excess intent- and urbanization-stratified US firearm deaths throughout the pandemic using inferential statistical methods. We estimate overall and intent- and urbanization-stratified excess US firearm mortality throughout the COVID-19 pandemic.
- 13 July 2023
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 6 (7) , e2323392
Open AccessExcess US Firearm Mortality During the COVID-19 Pandemic Stratified by Intent and Urbanization
Published research1,2 suggests the COVID-19 pandemic exacerbated already increasing rates of overall US firearm mortality. Descriptive comparisons of 2019 to 2020 mortality data suggest this early trend was driven by homicides and urban firearm deaths.2 However, to our knowledge, no study has quantified excess intent- and urbanization-stratified US firearm deaths throughout the pandemic using inferential statistical methods. We estimate overall and intent- and urbanization-stratified excess US firearm mortality throughout the COVID-19 pandemic.